Search

Your search keyword '"van Marum, Rob J."' showing total 434 results
Start Over Author "van Marum, Rob J."
434 results on '"van Marum, Rob J."'

1. A deprescribing programme aimed to optimise blood glucose-lowering medication in older people with type 2 diabetes mellitus, the OMED2-study: the study protocol for a randomised controlled trial

Author

Andriessen, Charlotte, Blom, Marieke T., van Hoek, Beryl A. C. E., de Boer, Anna W., Denig, Petra, de Wit, G. Ardine, Swart, Karin, de Rooij-Peek, Angela, van Marum, Rob J., Hugtenburg, Jacqueline G., Slottje, Pauline, van Raalte, Daniël, van Bloemendaal, Liselotte, Herings, Ron, Nijpels, Giel, Vos, Rimke C., and Elders, Petra J. M.

Published
2024
Full Text
View/download PDF

3. The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial

Author

van Balen, Dorieke E.M., Schutte, Peter F., Sigtermans, Marnix J., Kuck, Emile M., van Kan, Erik J.M., van der Steen, Marijke S., Bosma, Liesbeth E., Nowitzky, Ralph O., Beishuizen, Albertus, Movig, Kris L.L., Wesselink, Elsbeth M., Lammers, Rick J.W., Lau, Cedric, Masselink, Joost B., Bosman, Rob J., de Lange, Dylan W., van Marum, Rob J., van der Sijs, Heleen, Franssen, Eric J.F., Kieft, Hans, van den Bergh, Walter M., Bult, Wouter, Renes, Maurits H., de Feiter, Peter W., Wils, Evert-Jan, Hunfeld, Nicole G.M., Mulder, Froukje, Duyvendak, Michiel, Bakker, Tinka, Klopotowska, Joanna E, Dongelmans, Dave A, Eslami, Saeid, Vermeijden, Wytze J, Hendriks, Stefaan, ten Cate, Julia, Karakus, Attila, Purmer, Ilse M, van Bree, Sjoerd H W, Spronk, Peter E, Hoeksema, Martijn, de Jonge, Evert, de Keizer, Nicolette F, and Abu-Hanna, Ameen

Published
2024
Full Text
View/download PDF

4. Deprescribing practices, habits and attitudes of geriatricians and geriatricians-in-training across Europe: a large web-based survey

Author

van Poelgeest, Eveline P., Seppala, Lotta J., Lee, Jihoo M., Bahat, Gülistan, Ilhan, Birkan, Lavan, Amanda H., Mair, Alpana, van Marum, Rob J., Onder, Graziano, Ryg, Jesper, Fernandes, Marília Andreia, Garfinkel, Doron, Guðmundsson, Aðalsteinn, Hartikainen, Sirpa, Kotsani, Marina, Montero-Errasquín, Beatriz, Neumann-Podczaska, Agnieszka, Pazan, Farhad, Petrovic, Mirko, Soulis, George, Vankova, Hana, Wehling, Martin, Wieczorowska–Tobis, Katarzyna, and van der Velde, Nathalie

Published
2022
Full Text
View/download PDF

5. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

Author

Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J. M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Crome, Peter, Guðmundsson, Adalsteinn, Knol, Wilma, Snijders, Birgitta M. G., O’Mahony, Denis, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, van der Velde, Nathalie, and Wehling, Martin

Published
2022
Full Text
View/download PDF

7. Impact of Drug Recalls on Patients in The Netherlands: A 5-Year Retrospective Data Analysis

Author

Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, van Marum, Rob J, Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, and van Marum, Rob J

Abstract

Drug recalls occur frequently and have the potential to impact considerable numbers of patients and healthcare providers. However, in the absence of a comprehensive overview the extent of conducted recalls and their impact on patients remains unknown. To address this, we developed a comprehensive overview of drug recalls affecting patients. We compiled this overview based on the drug recall registrations from the Jeroen Bosch Hospital (JBZ), the University Medical Center Utrecht (UMCU), and the Royal Dutch Pharmacists Association (KNMP). A retrospective data analysis was conducted to identify drug recalls that affected patients. Specifically, we defined these as drug recalls that required patients to actively switch their drug to a different batch or brand of the same drug or to switch to a drug within the same or a different class of drugs. To quantify the impact, we used real-world drug dispensing data. Between January 1, 2017, and December 31, 2021, we identified 48 drug recalls that necessitated patients to make active changes to their medications an estimated 855,000 times. Most of the affected patients (292,000) were required to switch to a different brand of the same drug, whereas in 95,000 cases patients had to switch to a drug from another drug class. Our study suggests that a significant number of patients are affected by drug recalls. Future efforts are needed to elucidate patients' experiences and preferences regarding drug recalls, which could provide valuable insights to aid decision-making by relevant (national) authorities concerning drug recalls.

Published
2024

8. Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance

Author

Alloush, Roba, van Lint, Jette, van Marum, Rob J., Hermens, Walter W. A. J. J., Jessurun, Naomi T., Alloush, Roba, van Lint, Jette, van Marum, Rob J., Hermens, Walter W. A. J. J., and Jessurun, Naomi T.

Abstract

BackgroundInformation on registered adverse drug reactions (ADRs) in hospitals may provide a large real-world data source that can be used to ensure patients' safety. This study aimed to assess the potential contribution of hospital registration of ADRs in electronic health records (EHR) to pharmacovigilance.Research design and methodsAn observational retrospective descriptive study using data from the Jeroen Bosch Hospital in the Netherlands in 2019. 'Serious and/or severe' and 'previously unknown' ADRs registered systematically in the corresponding field of EHRs were assessed.ResultsADR data concerning 1010 patients were included. In total, 1630 ADRs were registered in EHRs. Fifty-eight serious and/or severe ADRs (5.2%) were registered. Tubulointerstitial nephritis was the most frequently registered severe ADR and was mainly associated with antibacterials for systemic use. A total of 82 previously unknown ADRs (5%) were registered. 'Migraine' and 'chest pain' were the most frequently registered unknown ADRs. Additionally, 25 ADRs (1.5%) were registered that may be attributable to 10 drugs 'under additional monitoring.'ConclusionsHospital registrations of ADRs in EHRs provide information on ADRs, which are challenging to assess during clinical trials. However, improvements are required to optimize this registration before it can serve as a valuable data source for pharmacovigilance purposes.

Published
2024

9. Impact of Drug Recalls on Patients in The Netherlands: A 5-Year Retrospective Data Analysis

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Pharmacoepidemiology and Clinical Pharmacology, Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, van Marum, Rob J, Afd Pharmacoepi & Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Pharmacoepidemiology and Clinical Pharmacology, Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, and van Marum, Rob J

Published
2024

10. Impact of Drug Recalls on Patients in The Netherlands: A 5‐Year Retrospective Data Analysis.

Author

Annema, Pieter A., Derijks, Hieronymus J., Bouvy, Marcel L., and van Marum, Rob J.

Subjects
DRUG recall, PATIENTS' attitudes, PATIENT experience, ACADEMIC medical centers, DRUG registration
Abstract

Drug recalls occur frequently and have the potential to impact considerable numbers of patients and healthcare providers. However, in the absence of a comprehensive overview the extent of conducted recalls and their impact on patients remains unknown. To address this, we developed a comprehensive overview of drug recalls affecting patients. We compiled this overview based on the drug recall registrations from the Jeroen Bosch Hospital (JBZ), the University Medical Center Utrecht (UMCU), and the Royal Dutch Pharmacists Association (KNMP). A retrospective data analysis was conducted to identify drug recalls that affected patients. Specifically, we defined these as drug recalls that required patients to actively switch their drug to a different batch or brand of the same drug or to switch to a drug within the same or a different class of drugs. To quantify the impact, we used real‐world drug dispensing data. Between January 1, 2017, and December 31, 2021, we identified 48 drug recalls that necessitated patients to make active changes to their medications an estimated 855,000 times. Most of the affected patients (292,000) were required to switch to a different brand of the same drug, whereas in 95,000 cases patients had to switch to a drug from another drug class. Our study suggests that a significant number of patients are affected by drug recalls. Future efforts are needed to elucidate patients' experiences and preferences regarding drug recalls, which could provide valuable insights to aid decision‐making by relevant (national) authorities concerning drug recalls. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial

Author

Bakker, Tinka, primary, Klopotowska, Joanna E, additional, Dongelmans, Dave A, additional, Eslami, Saeid, additional, Vermeijden, Wytze J, additional, Hendriks, Stefaan, additional, ten Cate, Julia, additional, Karakus, Attila, additional, Purmer, Ilse M, additional, van Bree, Sjoerd H W, additional, Spronk, Peter E, additional, Hoeksema, Martijn, additional, de Jonge, Evert, additional, de Keizer, Nicolette F, additional, Abu-Hanna, Ameen, additional, van Balen, Dorieke E.M., additional, Schutte, Peter F., additional, Sigtermans, Marnix J., additional, Kuck, Emile M., additional, van Kan, Erik J.M., additional, van der Steen, Marijke S., additional, Bosma, Liesbeth E., additional, Nowitzky, Ralph O., additional, Beishuizen, Albertus, additional, Movig, Kris L.L., additional, Wesselink, Elsbeth M., additional, Lammers, Rick J.W., additional, Lau, Cedric, additional, Masselink, Joost B., additional, Bosman, Rob J., additional, de Lange, Dylan W., additional, van Marum, Rob J., additional, van der Sijs, Heleen, additional, Franssen, Eric J.F., additional, Kieft, Hans, additional, van den Bergh, Walter M., additional, Bult, Wouter, additional, Renes, Maurits H., additional, de Feiter, Peter W., additional, Wils, Evert-Jan, additional, Hunfeld, Nicole G.M., additional, Mulder, Froukje, additional, and Duyvendak, Michiel, additional

Published
2024
Full Text
View/download PDF

13. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

Author

Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J. M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean-Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean-Baptiste, van der Velde, Nathalie, and Wehling, Martin

Published
2021
Full Text
View/download PDF

19. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project

Author

Willemse, Eline A.J., van Maurik, Ingrid S., Tijms, Betty M., Bouwman, Femke H., Franke, Andreas, Hubeek, Isabelle, Boelaarts, Leo, Claus, Jules J., Korf, Esther S.C., van Marum, Rob J., Roks, Gerwin, Schoonenboom, Niki, Verwey, Nicolaas, Zwan, Marissa D., Wahl, Simone, van der Flier, Wiesje M., and Teunissen, Charlotte E.

Published
2018
Full Text
View/download PDF

20. Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

Author

Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J. M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean-Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean-Baptiste, van der Velde, Nathalie, and Wehling, Martin

Published
2021
Full Text
View/download PDF

21. Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis

Author

Palmer, Katie, Villani, Emanuele R., Vetrano, Davide L., Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Curtin, Denis, Denkinger, Michael, Gutiérrez-Valencia, Marta, Guðmundsson, Adalsteinn, Knol, Wilma, Mak, Diane V., O’Mahony, Denis, Pazan, Farhad, Petrovic, Mirko, Rajkumar, Chakravarthi, Topinkova, Eva, Trevisan, Catarina, van der Cammen, Tischa J. M., van Marum, Rob J., Wehling, Martin, Ziere, Gijsbertus, Bernabei, Roberto, Onder, Graziano, and On behalf of the European Geriatric Medicine Society Pharmacology special interest group

Published
2019
Full Text
View/download PDF

23. Effect of conventional hemodialysis on the apixaban plasma concentration.

Author

Poel, Tim, de Rouw, Nikki, Péquériaux, Nathalie C. V., van de Kerkhof, Daan, Windsant, Annemieke M.A. Vermeulen, van Marum, Rob J., and Kerckhoffs, Angele P. M.

Subjects
APIXABAN, LOW-molecular-weight heparin, BLOOD plasma, HEMODIALYSIS, HEMODIALYSIS patients, DIALYSIS (Chemistry)
Abstract

Purpose: Apixaban is a factor Xa inhibitor used in patients undergoing hemodialysis treatment. The objective of this study is to investigate the effect of hemodialysis on apixaban plasma concentrations. Methods: This observational study is on patients treated with apixaban 2.5 mg twice daily on conventional hemodialysis with standard low‐molecular‐weight heparin (LMWH) anticoagulation (nadroparin 3800–7600 IU). Plasma blood samples were collected before starting dialysis (t1), 2 h after starting dialysis (t2), and directly after dialysis (t3). Apixaban concentration was measured before and after dialysis. Anti‐Xa activity was measured for all three samples. Results: A significant difference was observed between the apixaban concentration before and after dialysis (mean before dialysis 141.03 ng/mL; mean after dialysis 102.71 ng/mL; p = 0.003). Nonetheless, both apixaban plasma concentrations and anti‐Xa levels remained within the reference range. Anti‐Xa levels had a strong correlation with the apixaban concentrations (r = 0.935, p = 0.000). Thus, anti‐Xa activity might be used as a surrogate for apixaban plasma concentration. Conclusion: There seems to be no need for dose adjustments of apixaban; co‐administration of LMWH next to apixaban might also be unnecessary. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Psychotropic drug treatment for agitated behaviour in dementia: what if the guideline prescribing recommendations are not sufficient? A qualitative study

Author

Dijk, Margaretha T, Tabak, Sarah, Hertogh, Cees M P M, Kok, Rob M., van Marum, Rob J, Zuidema, Sytse U, Sizoo, Eefje M, Smalbrugge, Martin, Elderly care medicine, APH - Aging & Later Life, APH - Quality of Care, and Life Course Epidemiology (LCE)

Subjects
Psychotropic Drugs, Aging, General Medicine, non-guideline treatment, decision making, older people, agitated behaviour in dementia, Physicians, qualitative, Quality of Life, focus group, Humans, Dementia, Practice Patterns, Physicians', Geriatrics and Gerontology, Aged
Abstract

Background Agitation is a common challenging behaviour in dementia with a negative influence on patient’s quality of life and a high caregiver burden. Treatment is often difficult. Current guidelines recommend restrictive use of psychotropic drug treatment, but guideline recommendations do not always suffice. Objective To explore how physicians decide on psychotropic drug treatment for agitated behaviour in dementia when the guideline prescribing recommendations are not sufficient. Methods We conducted five online focus groups with a total of 22 elderly care physicians, five geriatricians and four old-age psychiatrists, in The Netherlands. The focus groups were thematically analysed. Results We identified five main themes. Transcending these themes, in each of the focus groups physicians stated that there is ‘not one size that fits all’. The five themes reflect physicians’ considerations when deciding on psychotropic drug treatment outside the guideline prescribing recommendations for agitated behaviour in dementia: (1) ‘reanalysis of problem and cause’, (2) ‘hypothesis of underlying cause and treatment goal’, (3) ‘considerations regarding drug choice’, (4) ‘trial and error’ and (5) ‘last resort: sedation’. Conclusion When guideline prescribing recommendations do not suffice, physicians start with reanalysing potential underlying causes. They try to substantiate and justify medication choices as best as they can with a hypothesis of underlying causes or treatment goal, using other guidelines, and applying personalised psychotropic drug treatment.

Published
2022

30. Personal Continuity and Appropriate Prescribing in Primary Care.

Author

te Winkel, Marije T., Damoiseaux-Volman, Birgit A., Abu-Hanna, Ameen, Lissenberg-Witte, Birgit I., van Marum, Rob J., Schers, Henk J., Slottje, Pauline, Uijen, Annemarie A., Bont, Jettie, and Maarsingh, Otto R.

Abstract

PURPOSE Personal continuity between patient and physician is a core value of primary care. Although previous studies suggest that personal continuity is associated with fewer potentially inappropriate prescriptions, evidence on continuity and prescribing in primary care is scarce. We aimed to determine the association between personal continuity and potentially inappropriate prescriptions, which encompasses potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs), by family physicians among older patients. METHODS We conducted an observational cohort study using routine care data from patients enlisted in 48 Dutch family practices from 2013 to 2018. All 25,854 patients aged 65 years and older having at least 5 contacts with their practice in 6 years were included. We calculated personal continuity using 3 established measures: the usual provider of care measure, the Bice-Boxerman Index, and the Herfindahl Index. We used the Screening Tool of Older Person's Prescriptions (STOPP) and the Screening Tool to Alert doctors to Right Treatment (START) specific to the Netherlands version 2 criteria to calculate the prevalence of potentially inappropriate prescriptions. To assess associations, we conducted multilevel negative binomial regression analyses, with and without adjustment for number of chronic conditions, age, and sex. RESULTS The patients' mean (SD) values for the usual provider of care measure, the Bice-Boxerman Continuity of Care Index, and the Herfindahl Index were 0.70 (0.19), 0.55 (0.24), and 0.59 (0.22), respectively. In our population, 72.2% and 74.3% of patients had at least 1 PIM and PPO, respectively; 30.9% and 34.2% had at least 3 PIMs and PPOs, respectively. All 3 measures of personal continuity were positively and significantly associated with fewer potentially inappropriate prescriptions. CONCLUSIONS A higher level of personal continuity is associated with more appropriate prescribing. Increasing personal continuity may improve the quality of prescriptions and reduce harmful consequences. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

Author

MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Crome, Peter, Guðmundsson, Adalsteinn, Knol, Wilma, Snijders, Birgitta M.G., O’Mahony, Denis, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, van der Velde, Nathalie, Wehling, Martin, MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Crome, Peter, Guðmundsson, Adalsteinn, Knol, Wilma, Snijders, Birgitta M.G., O’Mahony, Denis, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, van der Velde, Nathalie, and Wehling, Martin

Published
2022

39. Clozapine Treatment During Pregnancy and the Postpartum Period: A Systematic Literature Review

Author

Beex-Oosterhuis, Marieke M, Van Gool, Arthur R, Heerdink, Eibert R, van Kesteren, Charlotte, van Marum, Rob J, Beex-Oosterhuis, Marieke M, Van Gool, Arthur R, Heerdink, Eibert R, van Kesteren, Charlotte, and van Marum, Rob J

Abstract

Objective: The objective of this systematic review was to provide a critical appraisal of the evidence related to the safety of clozapine for schizophrenia during pregnancy and lactation.Data Sources: PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception through December 2020. Reference lists of included studies were hand-searched. The International Clinical Trials Registry Platform and ClinicalTrials.gov were searched for unpublished trials, and PROSPERO was searched for unpublished reviews. The current marketing authorization holder of the originator brands Clozaril and Leponex was also contacted for pharmacovigilance data.Study Selection: Original reports published in English, German, French, or Dutch containing clinical and preclinical data were included if they provided data on maternal, fetal, and neonatal outcomes after clozapine exposure during pregnancy or lactation.Data Extraction: Two reviewers independently extracted relevant data.Results: A total of 860 records were identified, and the full texts of 117 articles were reviewed. Forty-two studies met the inclusion criteria. Data on perinatal clozapine exposure are of limited quality and quantity. Although clozapine demonstrates partial placental passage, data thus far do not support that clozapine is teratogenic; that it increases the risk of stillbirth, abortion, or fetal disorders; or that it increases the risk of delivery complications or premature birth. Information about clozapine exposure through breast milk is scarce, but based on its chemical properties, it is likely that clozapine enters the breast milk of nursing mothers taking clozapine.Conclusions: When weighing the risks and benefits of clozapine continuation during pregnancy and lactation versus switching to another antipsychotic, one should include severity of illness and treatment history but also be aware of the limitations of the available safety data regarding perinatal cloza

Published
2021

40. Polyfarmacie bij ouderen: Artikel voor onderwijs en opleiding

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Van Marum, Rob J., Burgers, Jako S., Bouvy, Marcel L., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Van Marum, Rob J., Burgers, Jako S., and Bouvy, Marcel L.

Published
2021

41. Psychotropic drug prescription rates in primary care for people with dementia from recorded diagnosis onwards

Author

Joling, Karlijn J., Koppel, Maud Ten, Van Hout, Hein P.J., Onwuteaka‐Philipsen, Bregje D., Francke, Anneke L., Verheij, Robert A., Twisk, Jos W.r., Van Marum, Rob J., Joling, Karlijn J., Koppel, Maud Ten, Van Hout, Hein P.J., Onwuteaka‐Philipsen, Bregje D., Francke, Anneke L., Verheij, Robert A., Twisk, Jos W.r., and Van Marum, Rob J.

Abstract

Background: Psychotropic drugs are frequently prescribed to people with dementia in nursing homes although severe adverse events and side effects are common. Less is known about the prevalence and types of psychotropic drug prescription in primary care for people with dementia. Objective: This study examined the prevalence of psychotropic drug prescriptions in primary care among persons with dementia from the year of diagnosis onwards. Methods: A longitudinal observational study using electronic health record (EHR) data was conducted. People with dementia were selected from EHR data of 451 general practices in the Netherlands. Age and gender-adjusted psychotropic drug prescription rates were calculated per 1000 person-years from the year the dementia diagnosis was first recorded in general practice up to 8 years after diagnosis. Results: Data of 15,687 patients were analyzed. The prescription rate of psychotropic drugs (not including antidementia drugs) was 420 per 1000 person-years (95% CI 409; 431) in the first year after the recorded dementia diagnosis, which increased to 801 per 1000 person-years (95% CI 649; 989) in the eighth year. The most frequently prescribed drugs were antidepressants, antipsychotics, and antidementia drugs, followed by anxiolytics, hypnotics, and antiepileptics. Conclusions: After a dementia diagnosis is recorded in general practice, the prevalence of psychotropic drug prescriptions is substantial and increases steadily during the disease trajectory of persons with dementia. Although the (in)appropriateness of prescribing was not assessed, these insights may stimulate primary care clinicians to (re)consider their prescription policy of psychotropics for people with dementia more carefully.

Published
2021

42. Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials (European Journal of Clinical Pharmacology, (2021), 77, 1, (1-12), 10.1007/s00228-020-02951-8)

Author

MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean Baptiste, van der Velde, Nathalie, Wehling, Martin, MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean Baptiste, van der Velde, Nathalie, and Wehling, Martin

Published
2021

43. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

Author

MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean Baptiste, van der Velde, Nathalie, Wehling, Martin, MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean Baptiste, van der Velde, Nathalie, and Wehling, Martin

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results